Schonfeld Strategic Advisors LLC Aptevo Therapeutics Inc. Transaction History

Schonfeld Strategic Advisors LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.17 - $0.38 $2,754 - $6,156	16,200 Added 11.34%	159,000 $28,000
Q3 2023 Nov 14, 2023	SELL	$0.31 - $1.78 $558 - $3,204	-1,800 Reduced 1.24%	142,800 $47,000
Q2 2023 Aug 14, 2023	BUY	$1.34 - $2.08 $1,072 - $1,664	800 Added 0.56%	144,600 $211,000
Q1 2023 May 15, 2023	BUY	$1.74 - $2.54 $2,958 - $4,318	1,700 Added 1.2%	143,800 $293,000
Q4 2022 Feb 14, 2023	SELL	$2.0 - $3.91 $9,600 - $18,768	-4,800 Reduced 3.27%	142,100 $329,000

Q3 2022 Nov 14, 2022	BUY	$3.12 - $4.59 $1,872 - $2,754	600 Added 0.41%	146,900 $447,000
Q2 2022 Aug 15, 2022	SELL	$3.26 - $6.3 $5,542 - $10,710	-1,700 Reduced 1.15%	146,300 $524,000
Q1 2022 May 16, 2022	SELL	$4.48 - $8.42 $38,976 - $73,254	-8,700 Reduced 5.55%	148,000 $869,000
Q4 2021 Feb 14, 2022	BUY	$6.48 - $17.49 $1.02 Million - $2.74 Million	156,700 New	156,700 $1.23 Million
Q2 2021 Aug 16, 2021	SELL	$21.85 - $30.0 $211,945 - $291,000	-9,700 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$27.86 - $40.59 $39,004 - $56,826	-1,400 Reduced 12.61%	9,700 $296,000
Q4 2020 Feb 16, 2021	BUY	$6.21 - $48.36 $68,931 - $536,796	11,100 New	11,100 $407,000

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $3.61M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.